Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY Total Liabilities
Everything the company owes to creditors and other parties.
Bristol-Myers Squibb CompanyNYSE: BMY
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities falls 15.4% from a year ago
Total liabilities stood at $65.32B at the end of Q2 FY2026, down 15.4% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.
Context
- Total liabilities amounted to 74.5% of total assets at the end of Q2 FY2026, down 7.0 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -15.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 71.53B USD
- Year-over-year change
- -6.1%
- 4-year CAGR
- -0.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.53B | -6.1% |
| FY2024 | 2024-12-31 | 76.22B | +16.1% |
| FY2023 | 2023-12-31 | 65.67B | -0.0% |
| FY2022 | 2022-12-31 | 65.7B | -10.4% |
| FY2021 | 2021-12-31 | 73.31B | — |
Total Liabilities vs competitors
How BMY compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -15.4% is the 10th highest of 11, against a peer median of +3.4%.
- Total liabilities amounts to 74.5% of total assets for BMY, versus a peer median of 69.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $141B USD | +2.7% | +4.1% | 104.3% | |
| Sep 2026 | $115.9B USD | +2.1% | +2.1% | 58.7% | |
| Jun 2026 | $115.64B USD | -1.2% | +6.2% | 57.5% | |
| Jun 2026 | $108.4B USD | +31.3% | +30.4% | 76.2% | |
| Jun 2026 | $87.82B USD | +28.3% | +10.1% | 67.7% | |
| Jun 2026 | $83.95B USD | +4.3% | +10.1% | 87.8% | |
| Jun 2026 | $80.09B USD | +28.5% | +6.0% | 65.6% | |
| Sep 2026 | $67.99B USD | -0.7% | +3.2% | 56.8% | |
| Jun 2026 | $65.32B USD | -15.4% | +2.9% | 74.5% | |
| Jun 2026 | £44.29B GBP | -28.0% | -3.5% | 72.2% | |
| Jun 2026 | $37.62B USD | +4.1% | -4.6% | 76.2% | |
| Peer median (excluding BMY) | — | +3.4% | +5.0% | 69.9% | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.98B | 9.12B | 11.46B | 10.35B | 10.21B |
| Short-term Investments | 3.24B | 130M | 816M | 513M | 464M |
| Net Receivables | 12.52B | 13.94B | 15.26B | 14.42B | 14.53B |
| Inventory | 2.1B | 2.34B | 2.66B | 2.56B | 2.69B |
| Other Current Assets | 1.43B | 1.74B | 1.56B | 1.94B | 1.5B |
| Total Current Assets | 33.26B | 27.27B | 31.77B | 29.78B | 29.39B |
| Property, Plant & Equipment (Net) | 6.97B | 7.48B | 8.04B | 8.36B | 9.13B |
| Goodwill | 20.5B | 21.15B | 21.17B | 21.72B | 21.75B |
| Intangible Assets | 42.78B | 36.36B | 27.49B | 23.64B | 19.1B |
| Long-term Investments | 2.71B | 2.19B | 2.5B | 2.51B | 2.51B |
| Tax Assets | 1.44B | 1.34B | 2.77B | 4.24B | 5.38B |
| Other Non-current Assets | 1.66B | 1.04B | 1.43B | 2.36B | 2.78B |
| Total Non-current Assets | 76.05B | 69.55B | 63.39B | 62.82B | 60.65B |
| Total Assets | 109.31B | 96.82B | 95.16B | 92.6B | 90.04B |
| Account Payables | 2.95B | 3.04B | 3.26B | 3.6B | 3.58B |
| Short-term Debt | 4.95B | 4.26B | 3.12B | 2.05B | 2.26B |
| Tax Payables | 754M | 942M | 1.37B | 1.51B | 979M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.48B | 11.99B | 12.79B | 14.6B | 14.63B |
| Total Current Liabilities | 21.87B | 21.89B | 22.26B | 23.77B | 23.42B |
| Long-term Debt | 39.61B | 35.06B | 36.65B | 47.6B | 42.85B |
| Deferred Tax Liabilities | 4.5B | 2.17B | 338M | 369M | 222M |
| Deferred Revenue (Non-current) | 326M | 283M | 300M | 230M | 169M |
| Other Non-current Liabilities | 6.13B | 5.05B | 4.59B | 2.87B | 3.05B |
| Total Non-current Liabilities | 51.44B | 43.81B | 43.41B | 52.44B | 48.12B |
| Total Liabilities | 73.31B | 65.7B | 65.67B | 76.22B | 71.53B |
| Common Stock | 292M | 292M | 292M | 292M | 292M |
| Retained Earnings | 23.82B | 25.5B | 28.77B | 14.91B | 16.9B |
| Accumulated OCI | (1.27B) | (1.28B) | (1.55B) | (1.24B) | (1.52B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 60M | 57M | 55M | 53M | 33M |
| Total Equity | 36.01B | 31.12B | 29.49B | 16.39B | 18.51B |
| Total Debt | 45.6B | 40.72B | 41.46B | 51.2B | 47.14B |
| Net Debt | 31.62B | 31.59B | 30B | 40.85B | 36.93B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.